Edible Garden AG vs Immucell
Immucell is the larger business, with $27.6m of revenue in fiscal 2025 against $12.8m for Edible Garden AG (2.2 times as much). Immucell grew faster (4.3% against -7.6%). Immucell kept more of each dollar of sales as profit: a net margin of -3.8% against -135.3%. Edible Garden AG carries less debt relative to equity (24.8% against 33.6%).
| Latest fiscal year | Edible Garden AGEDBL, 2025 | ImmucellICCC, 2025 |
|---|---|---|
| Revenue | $12.8m | $27.6m |
| Revenue growth | -7.6% | 4.3% |
| Net income | −$17.3m | −$1.0m |
| Operating margin | -123.3% | 6.0% |
| Net margin | -135.3% | -3.8% |
| Return on equity | — | -3.8% |
| Free cash flow | −$12.4m | $1.2m |
| Cash | $1.1m | $3.8m |
| Total debt | $3.1m | $9.1m |
| Debt to equity | 24.8% | 33.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 95 | 73 |
| Market value | $370,207 | $95.8m |
| Price vs our value range | — | Above our value range |
| Moat score | 18 (Weak) | 34 (Weak) |
| Insider trades, 12 months | 9 buys, 1 sales | 8 buys, 0 sales |